Clinical trials: Immunologic Deficiency Syndrome
HIV Infections
Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany
This is a prospective, non-interventional, multi-center study, in participants with clinical indication of Human Immunodeficiency Virus (HIV)-1 infection.
- Trial name
- URBAN (NCT03754803)
- Testing
- HIV symptom distress module (SDM) questionnaire, HIV treatment satisfaction questionnaire (TSQ)
- Where
- 18 sites in Germany
- Volunteers
- 376 people
- Sponsor
- ViiV Healthcare
HIV-1 Infection
Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)
This study will evaluate the safety, tolerability and pharmacokinetics (PK) of 6 once-monthly doses of oral islatravir (60 mg and 120 mg) compared with placebo in adults at low risk of HIV-1 infection
- Trial name
- NCT04003103
- Testing
- Islatravir
- Where
- 9 sites in United States, Israel and 1 more
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Combination Vaccination Before HIV Treatment Interruption
The purpose of this study is to determine if vaccination before a structured treatment interruption (STI) is associated with an improvement in immune function, resulting in a delayed and reduced rebound in the amount of HIV virus…
- Trial name
- NCT00212888
- Testing
- Remune and ALVAC
- Where
- 3 sites in Canada
- Volunteers
- 52 people
- Sponsor
- Ottawa Hospital Research Institute
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance
Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
The purpose of the study is to determine if the combination of recombinant human growth hormone plus rosiglitazone (an insulin-sensitizing drug) is safe and more effective than either drug alone (or no active therapy) for the…
- Conditions
- HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X
- Trial name
- NCT00130286
- Testing
- Rosiglitazone, Recombinant human growth hormone + rosiglitazone
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- Weill Medical College of Cornell University
HIV Infections
Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients
The purpose of this study is to identify an optimal dose combination(s) of tipranavir (TPV) and ritonavir (RTV) for antiretroviral treatment naïve HIV-1 infected patients that can be used in pivotal trial by assessing the…
- Trial name
- NCT00530920
- Testing
- tipranavir, ritonavir
- Where
- 12 sites in Germany, Italy and 1 more
- Volunteers
- 85 people
- Sponsor
- Boehringer Ingelheim
IFN-Gamma Therapy, CGD Gene Mutation
Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease
Background: Chronic granulomatous disease (CGD) is an immunodeficiency disease in which white blood cells are unable to kill certain bacteria and fungi.
- Conditions
- IFN-Gamma Therapy, CGD Gene Mutation, CGD Response to IFNg, CGD - Chronic Granulomatous Disease
- Trial name
- NCT01147042
- Testing
- IFN-gamma
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART
Antiretroviral therapy (ART) dramatically reduces Human Immunodeficiency Virus (HIV) replication leading to restoration of immune function and a near normal life expectancy, but treatment is lifelong and there is no cure.
- Trial name
- NCT03198559
- Testing
- Disulfiram, (National Drug Code) NDC 0378-4141-01, Vorinostat, NDC 00006-0568-40
- Where
- Australia
- Volunteers
- 5 people
- Sponsor
- University of Melbourne
Acquired Immune Deficiency Syndrome, AIDS
Pilot Study of a Raltegravir Based NRTI Sparing Regimen
This pilot study will provide data on the safety and efficacy of the combination of Raltegravir (RAL) 400mg BID + Atazanavir (ATV) 300 mg BID in Antiretroviral (ARV)-experienced subjects that have a suppressed HIV viral load on a…
- Conditions
- Acquired Immune Deficiency Syndrome, AIDS, Human Immunodeficiency Virus, HIV Infections
- Trial name
- NCT00814879
- Testing
- Raltegravir, Atazanavir, Standard treatment regimen
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Yale University
Tobacco Use Cessation
Mobile Media-Rich Interactive Guideline System (MMRIGS) Pilot Study
The goal of this research study is to learn about 2 different interactive methods that are designed to help people with HIV/AIDS stop smoking.
- Trial name
- NCT02302859
- Testing
- Nicotine Patch, Questionnaires, Pamphlet
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Human Immunodeficiency Virus (HIV)
Romidepsin Plus 3BNC117 Phase 2a Study
The aim of this protocol is to evaluate the effects of romidepsin plus 3BNC117 or romidepsin alone on delaying or preventing viral rebound in ART-treated HIV-1-infected individuals during an analytical interruption of ART.
- Trial name
- ROADMAP (NCT02850016)
- Testing
- 3BNC117, Romidepsin
- Where
- 3 sites in United States, Denmark and 1 more
- Volunteers
- 48 people
- Sponsor
- Rockefeller University
HIV Infections, Episodic Substance Use
Reducing HIV Risk Among Episodic Substance Using Men Who Have Sex With Men (SUMSM)
The purpose of this study is to determine if persons randomized to receive adapted Personalized Cognitive Risk-reduction Counseling (PCC) will report greater reductions in unprotected anal sex behavior compared with persons who…
- Trial name
- NCT01279044
- Testing
- Adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC), Standard HIV testing with information only
- Where
- United States
- Volunteers
- 385 people, healthy volunteers welcome
- Sponsor
- San Francisco Department of Public Health
Hypertriglyceridemia, HIV Infection
Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
In subjects on boosted protease inhibitor (PI)-regimens who have elevated triglycerides, a switch to fosamprenavir/ritonavir once daily followed by the addition of Lovaza will result in 30% of patients achieving a reduction in…
- Trial name
- BuLLET (NCT01010399)
- Testing
- Lovaza, fosamprenavir/ritonavir
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Felizarta, Franco, M.D.
HIV Infections
Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children
The primary purpose of this study is to find the dose of Efavirenz for young children. The safety and how the medication is tolerated will also be studied.
- Trial name
- NCT00364793
- Testing
- Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
- Where
- 17 sites in Argentina, Colombia and 4 more
- Volunteers
- 56 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections, Hepatitis C
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)
The primary objective of this trial is to compare the efficacy of boceprevir (SCH 503034) 800 mg three times a day (TID) orally (PO) in combination with peginterferon alfa-2b (PegIFN-2b) 1.5 µg/kg weekly (QW) subcutaneously (SC)…
- Conditions
- HIV Infections, Hepatitis C, HCV Infection
- Trial name
- NCT00959699
- Testing
- PegIFN-2b, RBV, Boceprevir
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
High Grade Anal Canal Squamous Intraepithelial Neoplasia, Human Immunodeficiency Virus
Development of a Health-Related Symptom Index for Participants With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions
This trial develops a health-related symptom index for participants with and either treated or monitored for anal high-grade squamous intraepithelial lesions.
- Trial name
- NCT04276935
- Testing
- Interview, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- AIDS Malignancy Consortium
HIV Infection, Cardiovascular Disease Risk
Cardiovascular Prevention for Persons With HIV
This study is funded by the American Heart Association. The goal of this research is to prevent early cardiovascular damage before symptoms develop for persons with HIV infection.
- Trial name
- NCT00982189
- Testing
- Pravastatin, Lisinopril
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Hennepin Healthcare Research Institute
HIV Infections
Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers
The objective of the current study is to investigate the effect of multiple oral daily doses of BI 201335 on the steady-state pharmacokinetics of darunavir co-administered with ritonavir.
- Trial name
- NCT01374802
- Testing
- Darunavir, Ritonavir, BI 201335
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
HIV/AIDS, Hypertension
Systems Analysis and Improvement Approach for the Hypertension Care Cascade
As undiagnosed and untreated hypertension is one of the largest drivers of cardiovascular disease in sub-Saharan Africa approaches are needed to optimize the hypertension care cascade.
- Trial name
- SAIA-HTN (NCT04088656)
- Testing
- Systems Analysis and Improvement Approach for Hypertension Screening and Treatment Optimization
- Where
- 16 sites in Mozambique
- Volunteers
- 305 people
- Sponsor
- University of Washington
HIV-1 Infection
Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults
The primary objectives of this study are: Part A: To evaluate the short-term antiviral activity of lenacapavir (formerly GS-6207) with respect to the maximum reduction of plasma HIV-1 RNA (log10 copies/mL) from Day 1 through Day…
- Trial name
- NCT03739866
- Testing
- Lenacapavir, B/F/TAF, TAF
- Where
- 12 sites in United States
- Volunteers
- 53 people
- Sponsor
- Gilead Sciences
AIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia
HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV
This randomized phase III trial studies how well human papillomavirus (HPV) vaccine therapy works in reducing high-grade cervical lesions in patients with human immunodeficiency virus (HIV) and HPV.
- Conditions
- AIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia, HIV Infection
- Trial name
- COVENANT (NCT03284866)
- Testing
- Laboratory Biomarker Analysis, Recombinant Human Papillomavirus Nonavalent Vaccine, Saline
- Where
- 6 sites in Kenya, Malawi and 3 more
- Volunteers
- 535 people
- Sponsor
- AIDS Malignancy Consortium
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.